Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals

Studies on treatment of community-acquired pneumonia (CAP) in China are scarce. We performed a study to investigate empiric antibiotic practices for patients hospitalized with CAP in China and the risk factors for treatment failure. Data were collected from a national Chinese hospitalization databas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical microbiology and infection 2018-06, Vol.24 (6), p.658.e1-658.e6
Hauptverfasser: Nie, X.M., Li, Y.S., Yang, Z.W., Wang, H., Jin, S.Y., Jiao, Y., Metersky, M.L., Huang, Y.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 658.e6
container_issue 6
container_start_page 658.e1
container_title Clinical microbiology and infection
container_volume 24
creator Nie, X.M.
Li, Y.S.
Yang, Z.W.
Wang, H.
Jin, S.Y.
Jiao, Y.
Metersky, M.L.
Huang, Y.
description Studies on treatment of community-acquired pneumonia (CAP) in China are scarce. We performed a study to investigate empiric antibiotic practices for patients hospitalized with CAP in China and the risk factors for treatment failure. Data were collected from a national Chinese hospitalization database. Adult patients who were diagnosed with CAP between 1 October 2014 and 30 September 2015 were identified. We studied initial empiric antibiotic regimens, microbiologic sampling, treatment failure, in-hospital mortality and length of hospital stay. We included 18 043 adult patients from 185 hospitals who met all the study inclusion criteria. The most common initial antibiotic regimen for CAP was monotherapy with a fluoroquinolone (14.8%, 2671/18 043). The most common initial antibiotic (used alone or in combination with other antibiotics) was levofloxacin (15.7%, 4597/29 278 (this denominator represents the total number of initial antibiotics)). The microbiologic sampling rate was 26.9% (4851/18 043). A total of 4050 (22.4%) of 18 043 patients experienced treatment failure. Multivariate logistic regression demonstrated that older age, male sex, coexisting lung cancer and use of regimens not covering atypical pathogens were risk factors for treatment failure. In-hospital mortality was 2.1% (380/18 043). The median hospital length of stay was 11 days (interquartile range, 8–15 days). Patients receiving Chinese guideline-adherent regimens had better outcomes, and atypical pathogen active regimens were associated with a lower treatment failure rate and shorter length of hospital stay.
doi_str_mv 10.1016/j.cmi.2017.09.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1946428869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X1730527X</els_id><sourcerecordid>1946428869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-ae81cabf5429e8dcfdf9cc6a07b24f344151a886413c7466c39c0b6afa60c80e3</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMovn-AG-nSTWvSZtIGVzL4GBDcKLgL6e0tc4dp00laYf69GWZ06eqexXcO3I-xG8EzwYW6X2XQUZZzUWZcZ1zII3YupNIpV1ocxyx0lZay-DpjFyGsOOd5UchTdpZXuuRiVp6zr0VPI9l1gt1AniCx_Ug1uTHGcYneDtukdT4B13VTRLephc1EHptk6HHqXE82oT6ZL6nHgMnShYFGuw5X7KSNB68P95J9Pj99zF_Tt_eXxfzxLYVCqzG1WAmwdTuTucaqgbZpNYCyvKxz2RZSipmwVaWkKKCUSsUW8FrZ1ioOFcfikt3tdwfvNhOG0XQUANdr26ObghFaKpnHBR1RsUfBuxA8tmbw1Fm_NYKbnVCzMlGo2Qk1XJsoNHZuD_NT3WHz1_g1GIGHPYDxyW9CbwIQ9oBNlASjaRz9M_8DoNSIGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1946428869</pqid></control><display><type>article</type><title>Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Nie, X.M. ; Li, Y.S. ; Yang, Z.W. ; Wang, H. ; Jin, S.Y. ; Jiao, Y. ; Metersky, M.L. ; Huang, Y.</creator><creatorcontrib>Nie, X.M. ; Li, Y.S. ; Yang, Z.W. ; Wang, H. ; Jin, S.Y. ; Jiao, Y. ; Metersky, M.L. ; Huang, Y.</creatorcontrib><description>Studies on treatment of community-acquired pneumonia (CAP) in China are scarce. We performed a study to investigate empiric antibiotic practices for patients hospitalized with CAP in China and the risk factors for treatment failure. Data were collected from a national Chinese hospitalization database. Adult patients who were diagnosed with CAP between 1 October 2014 and 30 September 2015 were identified. We studied initial empiric antibiotic regimens, microbiologic sampling, treatment failure, in-hospital mortality and length of hospital stay. We included 18 043 adult patients from 185 hospitals who met all the study inclusion criteria. The most common initial antibiotic regimen for CAP was monotherapy with a fluoroquinolone (14.8%, 2671/18 043). The most common initial antibiotic (used alone or in combination with other antibiotics) was levofloxacin (15.7%, 4597/29 278 (this denominator represents the total number of initial antibiotics)). The microbiologic sampling rate was 26.9% (4851/18 043). A total of 4050 (22.4%) of 18 043 patients experienced treatment failure. Multivariate logistic regression demonstrated that older age, male sex, coexisting lung cancer and use of regimens not covering atypical pathogens were risk factors for treatment failure. In-hospital mortality was 2.1% (380/18 043). The median hospital length of stay was 11 days (interquartile range, 8–15 days). Patients receiving Chinese guideline-adherent regimens had better outcomes, and atypical pathogen active regimens were associated with a lower treatment failure rate and shorter length of hospital stay.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1016/j.cmi.2017.09.014</identifier><identifier>PMID: 28970157</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Age Factors ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Antibiotic therapy ; Atypical pathogen covering ; China ; Community-Acquired Infections ; Community-acquired pneumonia ; Female ; Fluoroquinolones - therapeutic use ; Hospital Mortality ; Hospitalization ; Humans ; Length of Stay ; Levofloxacin - therapeutic use ; Logistic Models ; Male ; Middle Aged ; Pneumonia - drug therapy ; Pneumonia - mortality ; Sex Factors ; Treatment Failure ; Young Adult</subject><ispartof>Clinical microbiology and infection, 2018-06, Vol.24 (6), p.658.e1-658.e6</ispartof><rights>2017 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-ae81cabf5429e8dcfdf9cc6a07b24f344151a886413c7466c39c0b6afa60c80e3</citedby><cites>FETCH-LOGICAL-c396t-ae81cabf5429e8dcfdf9cc6a07b24f344151a886413c7466c39c0b6afa60c80e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28970157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nie, X.M.</creatorcontrib><creatorcontrib>Li, Y.S.</creatorcontrib><creatorcontrib>Yang, Z.W.</creatorcontrib><creatorcontrib>Wang, H.</creatorcontrib><creatorcontrib>Jin, S.Y.</creatorcontrib><creatorcontrib>Jiao, Y.</creatorcontrib><creatorcontrib>Metersky, M.L.</creatorcontrib><creatorcontrib>Huang, Y.</creatorcontrib><title>Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Studies on treatment of community-acquired pneumonia (CAP) in China are scarce. We performed a study to investigate empiric antibiotic practices for patients hospitalized with CAP in China and the risk factors for treatment failure. Data were collected from a national Chinese hospitalization database. Adult patients who were diagnosed with CAP between 1 October 2014 and 30 September 2015 were identified. We studied initial empiric antibiotic regimens, microbiologic sampling, treatment failure, in-hospital mortality and length of hospital stay. We included 18 043 adult patients from 185 hospitals who met all the study inclusion criteria. The most common initial antibiotic regimen for CAP was monotherapy with a fluoroquinolone (14.8%, 2671/18 043). The most common initial antibiotic (used alone or in combination with other antibiotics) was levofloxacin (15.7%, 4597/29 278 (this denominator represents the total number of initial antibiotics)). The microbiologic sampling rate was 26.9% (4851/18 043). A total of 4050 (22.4%) of 18 043 patients experienced treatment failure. Multivariate logistic regression demonstrated that older age, male sex, coexisting lung cancer and use of regimens not covering atypical pathogens were risk factors for treatment failure. In-hospital mortality was 2.1% (380/18 043). The median hospital length of stay was 11 days (interquartile range, 8–15 days). Patients receiving Chinese guideline-adherent regimens had better outcomes, and atypical pathogen active regimens were associated with a lower treatment failure rate and shorter length of hospital stay.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic therapy</subject><subject>Atypical pathogen covering</subject><subject>China</subject><subject>Community-Acquired Infections</subject><subject>Community-acquired pneumonia</subject><subject>Female</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Hospital Mortality</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Levofloxacin - therapeutic use</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pneumonia - drug therapy</subject><subject>Pneumonia - mortality</subject><subject>Sex Factors</subject><subject>Treatment Failure</subject><subject>Young Adult</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAUhYMovn-AG-nSTWvSZtIGVzL4GBDcKLgL6e0tc4dp00laYf69GWZ06eqexXcO3I-xG8EzwYW6X2XQUZZzUWZcZ1zII3YupNIpV1ocxyx0lZay-DpjFyGsOOd5UchTdpZXuuRiVp6zr0VPI9l1gt1AniCx_Ug1uTHGcYneDtukdT4B13VTRLephc1EHptk6HHqXE82oT6ZL6nHgMnShYFGuw5X7KSNB68P95J9Pj99zF_Tt_eXxfzxLYVCqzG1WAmwdTuTucaqgbZpNYCyvKxz2RZSipmwVaWkKKCUSsUW8FrZ1ioOFcfikt3tdwfvNhOG0XQUANdr26ObghFaKpnHBR1RsUfBuxA8tmbw1Fm_NYKbnVCzMlGo2Qk1XJsoNHZuD_NT3WHz1_g1GIGHPYDxyW9CbwIQ9oBNlASjaRz9M_8DoNSIGw</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Nie, X.M.</creator><creator>Li, Y.S.</creator><creator>Yang, Z.W.</creator><creator>Wang, H.</creator><creator>Jin, S.Y.</creator><creator>Jiao, Y.</creator><creator>Metersky, M.L.</creator><creator>Huang, Y.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201806</creationdate><title>Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals</title><author>Nie, X.M. ; Li, Y.S. ; Yang, Z.W. ; Wang, H. ; Jin, S.Y. ; Jiao, Y. ; Metersky, M.L. ; Huang, Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-ae81cabf5429e8dcfdf9cc6a07b24f344151a886413c7466c39c0b6afa60c80e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic therapy</topic><topic>Atypical pathogen covering</topic><topic>China</topic><topic>Community-Acquired Infections</topic><topic>Community-acquired pneumonia</topic><topic>Female</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Hospital Mortality</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Levofloxacin - therapeutic use</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pneumonia - drug therapy</topic><topic>Pneumonia - mortality</topic><topic>Sex Factors</topic><topic>Treatment Failure</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nie, X.M.</creatorcontrib><creatorcontrib>Li, Y.S.</creatorcontrib><creatorcontrib>Yang, Z.W.</creatorcontrib><creatorcontrib>Wang, H.</creatorcontrib><creatorcontrib>Jin, S.Y.</creatorcontrib><creatorcontrib>Jiao, Y.</creatorcontrib><creatorcontrib>Metersky, M.L.</creatorcontrib><creatorcontrib>Huang, Y.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nie, X.M.</au><au>Li, Y.S.</au><au>Yang, Z.W.</au><au>Wang, H.</au><au>Jin, S.Y.</au><au>Jiao, Y.</au><au>Metersky, M.L.</au><au>Huang, Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2018-06</date><risdate>2018</risdate><volume>24</volume><issue>6</issue><spage>658.e1</spage><epage>658.e6</epage><pages>658.e1-658.e6</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Studies on treatment of community-acquired pneumonia (CAP) in China are scarce. We performed a study to investigate empiric antibiotic practices for patients hospitalized with CAP in China and the risk factors for treatment failure. Data were collected from a national Chinese hospitalization database. Adult patients who were diagnosed with CAP between 1 October 2014 and 30 September 2015 were identified. We studied initial empiric antibiotic regimens, microbiologic sampling, treatment failure, in-hospital mortality and length of hospital stay. We included 18 043 adult patients from 185 hospitals who met all the study inclusion criteria. The most common initial antibiotic regimen for CAP was monotherapy with a fluoroquinolone (14.8%, 2671/18 043). The most common initial antibiotic (used alone or in combination with other antibiotics) was levofloxacin (15.7%, 4597/29 278 (this denominator represents the total number of initial antibiotics)). The microbiologic sampling rate was 26.9% (4851/18 043). A total of 4050 (22.4%) of 18 043 patients experienced treatment failure. Multivariate logistic regression demonstrated that older age, male sex, coexisting lung cancer and use of regimens not covering atypical pathogens were risk factors for treatment failure. In-hospital mortality was 2.1% (380/18 043). The median hospital length of stay was 11 days (interquartile range, 8–15 days). Patients receiving Chinese guideline-adherent regimens had better outcomes, and atypical pathogen active regimens were associated with a lower treatment failure rate and shorter length of hospital stay.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28970157</pmid><doi>10.1016/j.cmi.2017.09.014</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1198-743X
ispartof Clinical microbiology and infection, 2018-06, Vol.24 (6), p.658.e1-658.e6
issn 1198-743X
1469-0691
language eng
recordid cdi_proquest_miscellaneous_1946428869
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Age Factors
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Antibiotic therapy
Atypical pathogen covering
China
Community-Acquired Infections
Community-acquired pneumonia
Female
Fluoroquinolones - therapeutic use
Hospital Mortality
Hospitalization
Humans
Length of Stay
Levofloxacin - therapeutic use
Logistic Models
Male
Middle Aged
Pneumonia - drug therapy
Pneumonia - mortality
Sex Factors
Treatment Failure
Young Adult
title Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A30%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Initial%20empiric%20antibiotic%20therapy%20for%20community-acquired%20pneumonia%20in%20Chinese%20hospitals&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Nie,%20X.M.&rft.date=2018-06&rft.volume=24&rft.issue=6&rft.spage=658.e1&rft.epage=658.e6&rft.pages=658.e1-658.e6&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1016/j.cmi.2017.09.014&rft_dat=%3Cproquest_cross%3E1946428869%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1946428869&rft_id=info:pmid/28970157&rft_els_id=S1198743X1730527X&rfr_iscdi=true